therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
22 Feb 2017
Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017 MORE
09 Feb 2017
Amarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference MORE
- AMRN (NASDAQ)
- Fri, 24 Feb 2017 16:00
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.